Aurobindo Pharma reported a 32.8% year-on-year increase in consolidated net profit to ₹1,126 crore for the second quarter of FY27, compared with ₹848 crore in the corresponding quarter last year.
The pharmaceutical company also reported its highest-ever quarterly revenue from operations, supported by growth across its key business segments. The results were ahead of CNBC-TV18 poll estimates across revenue, profit and operating earnings.
Revenue from operations increased 23.9% to ₹10,263 crore from ₹8,286 crore a year ago. The figure was higher than the CNBC-TV18 poll estimate of ₹9,719 crore.
Earnings before interest, tax, depreciation and amortisation (EBITDA) rose 28.4% year on year to ₹2,155 crore, compared with ₹1,678 crore in the year-ago quarter. This was also above the CNBC-TV18 poll estimate of ₹2,006 crore. EBITDA margin expanded to 21% from 20.3% a year ago, against the poll estimate of 20.6%.
Growth across key markets
The company’s US revenue increased 25% year on year to ₹4,555 crore, equivalent to $477 million. Europe revenue grew 27% to ₹3,161 crore, or €288 million, while revenue from growth markets rose 16% to ₹1,026 crore, equivalent to $107 million.
Revenue from antiretroviral (ARV) products stood at ₹359 crore, or $38 million, during the quarter.
Aurobindo Pharma received final approval from the United States Food and Drug Administration (USFDA) for 12 products during the quarter. Research and development expenditure stood at ₹376 crore, compared with ₹344 crore in the previous quarter.
Cash position and dividend
The company generated free cash flow of $146 million during the quarter after accounting for strategic capital expenditure investments. Its net cash position, including investments, stood at $189 million as of September 30, 2026.
Basic and diluted earnings per share stood at ₹19.57.
The board approved an interim dividend of ₹7 per equity share of face value ₹1 each, equivalent to 700%. November 11, 2026, has been fixed as the record date for determining shareholders eligible for the dividend. The payment will be made on or before November 20, 2026.
Management commentary
Commenting on the performance, K. Nithyananda Reddy, Vice-Chairman and Managing Director of Aurobindo Pharma, said the quarterly performance reflected the company’s business fundamentals, execution and diversified product portfolio.
He attributed the growth to organic momentum across key businesses and the integration of inorganic opportunities, which he said had strengthened the company’s capabilities. Reddy added that the company would remain focused on its strategic priorities, financial discipline and long-term value creation.
Aurobindo Pharma shares closed 0.62% higher at ₹1,705 on November 4, ahead of earning announcement.
Also Read: Dow soars 1,000 points as investors love Democrats’ midterm sweep; Wall Street rallies
KIMS Q2 net profit rises 12% to ₹75 crore, revenue jumps 40% but margin declines
Nov 4, 2026
Afcons Infrastructure Q2 results: Net profit falls 60.7% to ₹41 crore, revenue down 11.8%
Nov 4, 2026
Kansai Nerolac Q2 results: Net profit rises 8.4% to ₹146 crore, revenue up 18.6%
Nov 4, 2026
Earnings Central: Lenskart, Nykaa, Aurobindo Pharma shine; PI Industries, Apollo Tyres face margin heat
Nov 4, 2026